Stock-Based Compensation for DexCom (DXCM)
Stock-Based Compensation for DexCom (DXCM): headline value $159.60M · YoY -6.3%. Annual and quarterly series, chart, and tables are below.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
DXCM
Currently viewingStock-Based CompensationSwitch metric
Latest period
$159.60M
YoY change
-6.3%
5Y CAGR
+6.0%
Peak year (2006)
$5.85B
Latest annual
$159.60M
Stock-Based Compensation history chart for DexCom (DXCM) from 2003 to 2025
Stock-Based Compensation history table for DexCom (DXCM) from 2003 to 2025
| Fiscal year | Period ended | Reported | Stock-Based Compensation | YoY |
|---|---|---|---|---|
| 2025 | $159.60M | -6.3% | ||
| 2024 | $170.40M | +13.0% | ||
| 2023 | $150.80M | +19.2% | ||
| 2022 | $126.50M | +11.6% | ||
| 2021 | $113.40M | -5.0% | ||
| 2020 | $119.40M | +16.3% | ||
| 2019 | $102.70M | +0.8% | ||
| 2018 | $101.90M | -4.0% | ||
| 2017 | $106.20M | -4.2% | ||
| 2016 | $110.80M | +34.0% | ||
| 2015 | $82.70M | +65.4% | ||
| 2014 | $50.00M | +103.3% | ||
| 2013 | $24.60M | +33.7% | ||
| 2012 | $18.40M | +36.2% | ||
| 2011 | $13.51M | +43.1% | ||
| 2010 | $9.44M | +12.8% | ||
| 2009 | $8.37M | +8.9% | ||
| 2008 | $7.68M | +25.5% | ||
| 2007 | $6.12M | -99.9% | ||
| 2006 | $5.85B | +251.4% | ||
| 2005 | $1.67B | — | ||
| 2004 | $0 | — | ||
| 2003 | $0 | — |
Stock-Based Compensation values are taken from DexCom's reported cash flow statements (10-Q quarterly and 10-K annual filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the date the filing was reported; YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
Analysis
DexCom (DXCM) most recent annual stock-based compensation stands at $159.60M (2025) – declined 6.3% year-over-year.
DexCom stock-based compensation has recorded the values shown across consecutive periods, with a +6.0% compound annual growth rate over 2020–2025 (5 years).
Across the available history, stock-based compensation reached its high of $5.85B in 2006 and its low of $0 in 2003.
Within Healthcare, DexCom (DXCM) ranks 5th among 8 peers we track. The peer median for stock-based compensation is $313.00M.
DexCom Stock-Based Compensation by Year
DexCom Stock-Based Compensation 2025: $159.60M
DexCom stock-based compensation in 2025 was $159.60M, declined 6.3% below 2024.
DexCom Stock-Based Compensation 2024: $170.40M
DexCom stock-based compensation in 2024 was $170.40M, grew 13.0% from 2023.
DexCom Stock-Based Compensation 2023: $150.80M
DexCom stock-based compensation in 2023 was $150.80M, grew 19.2% from 2022.
DexCom Stock-Based Compensation 2022: $126.50M
DexCom stock-based compensation in 2022 was $126.50M, grew 11.6% from 2021.
DexCom Stock-Based Compensation 2021: $113.40M
DexCom stock-based compensation in 2021 was $113.40M.
See more financial history for DexCom (DXCM).
Sector peers — Stock-Based Compensation
Companies in the same sector as DexCom, ranked by their latest stock-based compensation.
| Company | Stock-Based Compensation | Sector |
|---|---|---|
| Johnson & Johnson (JNJ) | $1.35B | Healthcare |
| UnitedHealth Group Incorporated (UNH) | $971.00M | Healthcare |
| AbbVie Inc. (ABBV) | $955.00M | Healthcare |
| Eli Lilly and Company (LLY) | $626.00M | Healthcare |
| AstraZeneca PLC (AZN) | $0 | Healthcare |
| Merck & Co., Inc. (MRK) | $0 | Healthcare |
| Amgen Inc. (AMGN) | $0 | Healthcare |
| Novo Nordisk A/S (NVO) | $0 | Healthcare |
Frequently asked questions
What is DexCom's stock-based compensation?
Latest reported stock-based compensation for DexCom (DXCM) is $159.60M (period ending December 31, 2025).
How has DexCom stock-based compensation changed year-over-year?
DexCom (DXCM) stock-based compensation changed -6.3% year-over-year on the latest annual filing.
What is the long-term growth rate of DexCom stock-based compensation?
DexCom (DXCM) stock-based compensation compound annual growth rate is +6.0% over the most recent 5 years available.
When did DexCom stock-based compensation hit its highest annual value?
DexCom stock-based compensation reached its highest annual value of $5.85B in 2006.
What was DexCom stock-based compensation in 2024?
DexCom (DXCM) stock-based compensation in 2024 was $170.40M.
What was DexCom stock-based compensation in 2025?
DexCom (DXCM) stock-based compensation in 2025 was $159.60M.
Metrics overview
Pick a metric for charts, filings and peers — each row shows the latest TTM or most-recent-quarter value.
Explore more
DXCM Overview
Company profile, financial tools, and key metrics
DXCM Revenue Counter
Earns $147.83 every second. See per minute, hour, and day.
DXCM Earnings Counter
Earns $26.52 per second net profit. See per minute, hour, and day.
DXCM Economic Scale
Exceeds Suriname's GDP. Compare with world economies.
DXCM What If Invested
What if you had invested $1,000? See historical returns from any date.
DXCM How It Makes Money
Discover visual breakdown of $4.66B in revenue — where it comes from and where it goes.
DXCM Stock Seasonality
Best and worst months to invest. Historical monthly returns heatmap.
DXCM Price Target Scenarios
Model bear, base, and bull cases with EPS growth and exit P/E — pre-filled from analysts and history.
DXCM Daily Price Character
Explosive · 49.4% historical win rate (green days). Streaks & record days.
DXCM Buybacks
1.95% TTM buyback yield. Shareholder yield & SBC comparison.
DXCM Stock Split History
1 split on record. Dates, ratios, and cumulative multiple.